在急性淋巴细胞白血病中,伊索伊佩拉托林通过调节PI3K/AKT通路抑制细胞增殖并诱导细胞亡
1Department of Hematology, Yantaishan Hospital, Yantai, Shandong 264003, China.
Molecular immunology
|December 19, 2025
概括
伊索伊佩拉托林 (ISOIM) 抑制T细胞急性淋巴细胞白血病 (T-ALL) 细胞生长,并通过抑制PI3K/AKT通路和减少PD-L1表达来促进细胞亡. 这为T-ALL.提供了一个新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- T细胞急性淋巴细胞白血病 (T-ALL) 是一种具有攻击性的血液性恶性瘤.
- 针对PI3K/AKT通路和PD-L1是T-ALL的一种有前途的治疗策略.
- 绝对素 (ISOIM) 是一种具有潜在抗癌功能的天然化合物.
研究的目的:
- 调查ISOIM对T-ALL细胞恶性表型的影响.
- 阐明PI3K/AKT通路和PD-L1在ISOIM的作用机制中的作用.
- 探索ISOIM作为T-ALL.的潜在治疗剂.
主要方法:
- 在体外测试 (CCK-8,EDU,流细胞计,TUNEL) 评估了T-ALL细胞的增殖和亡.
- 网络药理学,分子对接和功能丰富分析确定了分子标.
- 西方涂抹评估了与亡,PD-L1和PI3K/AKT通路相关的蛋白质表达.
主要成果:
- ISOIM显著抑制了T-ALL细胞的增殖和诱导的亡.
- 凯格和GO的分析将ISOIM目标与PD-1检查点和PI3K/AKT通路联系起来.
- ISOIM降低了PD-L1,p-PI3K,p-AKT和p-mTOR水平,而PI3K/AKT激活剂可以逆转这些影响.
结论:
- 通过抑制PI3K/AKT通路和减少PD-L1.1,ISOIM可以抑制T-ALL细胞的恶性行为.
- 这项研究为开发基于ISOIM的T-ALL治疗提供了理由.
- ISOIM显示出作为T-ALL.新型治疗策略的潜力.
关键词:
急性淋巴细胞白血病 (Acute Lymphoblastic Leukemia) 是一种急性淋巴细胞白血病.细胞亡是细胞的亡.在Isoimperator中在PD-L1中.通过PI3K/AKT路径.更多相关视频
08:49Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
9.5K
09:09Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation
Published on: November 10, 2017
8.7K
相关概念视频
The Intrinsic Apoptotic Pathway
8.2K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.2K
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
PI3K/mTOR/AKT Signaling Pathway
5.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.3K
The Extrinsic Apoptotic Pathway
8.0K
The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
8.0K
Combination Therapies and Personalized Medicine
5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
The JAK-STAT Signaling Pathway
11.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
11.8K
